|
Registered
Join Date: Jan 2002
Location: Nor California & Pac NW
Posts: 24,806
|
On the therapeutic side, it seems to me if the patient pool is 500K/yr (hospitalized in the US) then the drug needs to command $10K/patient. Because not every hospitalized patient will get it. 500K x $10,000 x 50% = $2.5BN. Transformative for a small biotech, not for a big pharma. As an investor, I am not sure why one should bet too much on a promising Covid therapeutic under development by, say, GSK or MRK. The same drug in the hands of a small cap company - sure, let's buy the stock.
__________________
1989 3.2 Carrera coupe; 1988 Westy Vanagon, Zetec; 1986 E28 M30; 1994 W124; 2004 S211
What? Uh . . . “he” and “him”?
|